Redcare Pharmacy stock falls as e-prescription growth contrasts with weak share demand
Published on 09/14/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Redcare Pharmacy stock (ISIN NL0012044747) is trading clearly below its early-2026 levels, with the share closing at 52.55 EUR on September 11, 2026, roughly 20 percent lower than at the start of the year according to an article summarizing recent performance.
Half-year 2026 figures show strong growth
According to Ad-hoc-news, Redcare Pharmacy reported a strong increase in revenue in the first half of 2026, with group sales rising 19 percent to 1.7 billion EUR compared with the same period a year earlier.
In Germany, revenue in the e-prescription related segment increased by 58 percent in the first half of 2026, highlighting how quickly the electronic prescription model is gaining traction in the domestic market per Ad-hoc-news.
The same report states that the number of active customers rose by 9 percent year-on-year to 14.7 million in the first six months of 2026, giving Redcare Pharmacy a broader base of repeat buyers and potentially improving customer lifetime value.
Guidance for 2026 and upcoming Q3 release
Management increased its full-year 2026 guidance in the summer, now targeting revenue growth of 15 to 17 percent and an adjusted EBITDA margin between 2.5 and 3.0 percent according to Ad-hoc-news.
The same source notes that Redcare Pharmacy plans to publish its third-quarter 2026 results on October 29, 2026, offering investors the next checkpoint to assess whether the company can deliver on its raised revenue and margin targets.
For investors, the combination of double-digit revenue growth, expanding customer numbers and a more ambitious margin target sets clear expectations for the upcoming quarterly report and increases the focus on execution in the e-prescription business.
Stock performance and market sentiment
Despite the solid operational momentum, the share price has struggled. As summarized by Ad-hoc-news, Redcare Pharmacy stock closed at 52.55 EUR on September 11, 2026, representing a decline of around 3.6 percent on that trading day.
According to Goldesel, the stock was quoted at 52.45 EUR on September 11, 2026, and was about 20.05 percent down year-to-date, underlining that the market has not yet rewarded the company’s operational progress.
An article on Finanznachrichten describes how buyers have pulled back after the share broke below a previous trading range at the beginning of September 2026, reflecting a cautious sentiment even as fundamentals improve.
Upcoming investor interaction
Redcare Pharmacy is also scheduled to participate in a Deutsche Bank non-deal roadshow event in Zurich on September 26, 2026, according to an overview on EQS News, giving management another chance to present the growth story to institutional investors ahead of the third-quarter release.
For investors, this upcoming interaction with the market could be an opportunity for more detailed discussion of how e-prescriptions, customer growth and margin improvements are expected to translate into medium-term profitability.
Redcare Pharmacy stock price as of September 11, 2026
Redcare Pharmacy stock last closed at 52.55 EUR on its primary listing in the Netherlands on September 11, 2026, based on data summarized in recent coverage; with the share around 20 percent below its level at the beginning of 2026, the price sits clearly beneath its highs of the past year.
Key data on Redcare Pharmacy stock
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC
- Trading venue: Euronext Amsterdam
- Price (as of September 11, 2026): 52.55 EUR
- Sector / Industry: Food and Drug Retailing
- Index membership: none (major index)
